TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36765421
Drug: Low-dose alteplase
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose alteplase infusion (24 h)
Study: 36765556
Drug: Calcium electroporation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium electroporation treatment
Study: 36765803
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for primary tumors of the spine
Study: 36769445
Drug: Low-dose radiotherapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radiotherapy (0.5 Gy)
Study: 36769543
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (first 4 weeks)
Study: 36769813
Drug: Traditional logistic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional logistic regression and eleven ML algorithms
Study: 36771199
Drug: Resveratrol supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol supplement
Study: 36772985
Drug: Trauma plasma-derived
Normalized name: Haptoglobulin 1/1 (Plasma Derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma plasma-derived exosomes (100 μg and 200 μg)
Study: 36772985
Drug: Trauma plasma-derived
Normalized name: Haptoglobulin 1/1 (Plasma Derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma plasma-derived exosomes (50 μg)
Study: 36772985
Drug: Trauma exosomal
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma exosomal protein (100 μg) with bone marrow stromal cells
Study: 36773112
Drug: Ceftolozane/tazobactam 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftolozane/tazobactam 3 g every 8 h for 8-14 days
Study: 36773112
Drug: Meropenem 1
Normalized name: meropenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 1 g every 8 h for 8-14 days
Study: 36774112
Drug: Herbs and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbs and spices at doses of 0.5, 3.3, and 6.6 g/day
Study: 36774905
Drug: Intranasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketamine at a dose of 6 mg/kg
Study: 36774933
Drug: Nivolumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (240 mg IV every 2 weeks for 12 doses) plus Ipilimumab (1 mg/kg IV every 6 weeks for four doses)
Study: 36775009
Drug: Fitbit Charge
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fitbit Charge 5 and daily text messages
Study: 36775980
Drug: Current treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current treatment with cardioprotective antidiabetic medication
Study: 36777769
Drug: Capecitabine maintenance
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine maintenance therapy plus best supportive care (CBSC)
Study: 36778595
Drug: Nutraceutical supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical supplements with yeast β-glucan, prebiotics, minerals
Study: 36778864
Drug: Anakinra (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (100 mg subcutaneously every 12 hours for 3 days, then 100 mg subcutaneously once daily for 4 days) in addition to standard of care (SOC)
Study: 36779003
Drug: Activity monitor
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activity monitor (Fitbit Charge 3) and custom weekly surveys
Study: 36779325
Drug: Hodgkin lymphoma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hodgkin lymphoma treatment
Study: 36779512
Drug: Magrolimab in
Normalized name: Magrolimab
DrugBank: Magrolimab (DB16225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magrolimab in combination with commonly used myeloma therapies
Study: 36779614
Drug: Aragonite-based osteochondral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aragonite-based osteochondral implant
Study: 36780159
Drug: SER-109 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: SER-109 (4 capsules daily for 3 days after symptom resolution following antibiotic treatment)
Study: 36780180
Drug: 1000 IU
Normalized name: D 1000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 IU per day of oral vitamin D3 supplementation
Study: 36780180
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU per day of oral vitamin D3 supplementation
Study: 36780265
Drug: Effective Skills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effective Skills to Empower Effective Men (ESTEEM); an LGBQ-affirmative transdiagnostic cognitive behavioral therapy (CBT)
Study: 36780610
Drug: T-DXd 5.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-DXd 5.4 mg/kg intravenously once every 3 weeks (n = 373)
Study: 36780610
Drug: Physicians' choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physicians' choice of chemotherapy (n = 184)
Study: 36780675
Drug: Difelikefalin 2
Normalized name: DIFELIKEFALIN
DrugBank: Difelikefalin (DB11938)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Difelikefalin 2 mg orally twice daily for 8 weeks
Study: 36780676
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon lambda (single subcutaneous injection, 180 μg)
Study: 36780676
Drug: Placebo (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (single injection or oral)
Study: 36780768
Drug: Medication Treatment
Normalized name: Acne Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Treatment for Opioid Use Disorder (MOUD) strategies
Study: 36781334
Drug: SCB-2019 (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCB-2019 (two doses administered intramuscularly 21 days apart)
Study: 36781334
Drug: SCB-2019 (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCB-2019 (one dose administered)
Study: 36781469
Drug: Pronase administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pronase administration
Study: 36781469
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no pronase administration)
Study: 36781774
Drug: Plerixafor-based hematopoietic
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plerixafor-based hematopoietic cell mobilization combined with granulocyte-colony stimulating factor (G-CSF)
Study: 36781928
Drug: Sarpogrelate plus
Normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpogrelate plus aspirin (300 mg orally once per day for 6 months)
Study: 36781928
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus aspirin (75 mg orally once per day for 6 months)
Study: 36782093
Drug: Sotagliflozin 200
Normalized name: sotagliflozin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotagliflozin 200 mg and 400 mg
Study: 36782134
Drug: Colorectal cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colorectal cancer survivors' recollections of their illness and treatment experiences after therapy
Study: 36782325
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin (1500 mg once weekly for 8 weeks)
Study: 36785526
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of antibiotic therapy (ofloxacin or third-generation cephalosporin)
Study: 36785526
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days of antibiotic therapy (ofloxacin or third-generation cephalosporin)
Study: 36785850
Drug: Two-dose PCV10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose PCV10 schedule (2,6 months)
Study: 36785850
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no infant doses of PCV)
Study: 36786049
Drug: Changing infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Changing infusion set every 0-4 days
Study: 36786049
Drug: Timing insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Timing insulin 10-15 min before meal
Study: 36786322
Drug: Medication-overuse headache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-overuse headache patients
Study: 36787013
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical management plus ReActiv8® restorative neurostimulation therapy
Study: 36787089
Drug: INCB062079 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB062079 15 mg twice daily
Study: 36787089
Drug: INCB062079 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB062079 10 mg once daily
Study: 36787124
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diuretics with varying pharmacological targets for diuretic resistance and sodium avidity
Study: 36787124
Drug: Invasive decongestion
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive decongestion methods including ultrafiltration or kidney replacement therapy (KRT) such as peritoneal dialysis
Study: 36787235
Drug: Mindfulness-based music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based music therapy intervention (4 sessions, 45 minutes each over 12 weeks)
Study: 36787249
Drug: Mosaic vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosaic vaccine
Study: 36787249
Drug: CON-S vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CON-S vaccine
Study: 36787249
Drug: Nat-B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nat-B vaccine
Study: 36787305
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg/day orally for 7 days
Study: 36787525
Drug: Estradiol cream
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol cream 50 μg
Study: 36787525
Drug: Estradiol cream
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol cream 100 μg
Study: 36788081
Drug: Short-term preoperative
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term preoperative endocrine therapy (pET; tamoxifen or aromatase inhibitor)
Study: 36788511
Drug: Topical TAC
Normalized name: triamcinolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical TAC 0.1% patch twice daily
Study: 36788511
Drug: Topical TAC
Normalized name: triamcinolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical TAC 0.1% gel
Study: 36788511
Drug: Topical TRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical TRI 0.1% gel four times daily
Study: 36789515
Drug: Cariprazine 1.5
Normalized name: cariprazine 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine 1.5 mg/day and 3.0 mg/day
Study: 36789577
Drug: Fexuprazan 20
Normalized name: fexuprazan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexuprazan 20 mg once a day (q.d.)
Study: 36789577
Drug: Fexuprazan 10
Normalized name: fexuprazan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexuprazan 10 mg twice a day (b.i.d.)
Study: 36789614
Drug: Antiplatelet agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet agent
Study: 36789614
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant vs. antiplatelet agent
Study: 36789945
Drug: FeFum+GOS (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: FeFum+GOS (5.0 mg iron with 3.0 g GOS)
Study: 36789945
Drug: FeFum+HMO (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: FeFum+HMO (5.0 mg iron with 3.0 g HMO)
Study: 36789945
Drug: FeFum (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: FeFum (5.0 mg iron without GOS or HMO)
Study: 36790457
Drug: High intake
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intake of total meat (≥ 108.57 g/day)
Study: 36790457
Drug: High intake
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intake of red/processed meat (≥ 74.29 g/day)
Study: 36790457
Drug: High intake
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intake of protein (≥ 65.05 g/day)
Study: 36790457
Drug: High intake
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intake of dietary iron (≥ 8.58 mg/day)
Study: 36790596
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg metformin with 10 mg baxdrostat
Study: 36790596
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg metformin alone
Study: 36790672
Drug: Low-level red-light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level red-light (RLRL) therapy
Study: 36791089
Drug: Self-applied treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-applied treatment for rat phobia supported by a Virtual Therapy Assistant (VTA)
Study: 36791161
Drug: Ad26.RSV.preF-RSV preF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.RSV.preF-RSV preF protein vaccine
Study: 39052726
Drug: RSVPreF3 OA
Normalized name: RSVPreF3 OA
DrugBank: Respiratory syncytial virus vaccine, adjuvanted (DB17762)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVPreF3 OA vaccine
Study: 36791162
Drug: BNT162b2 vaccine
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 vaccine (3-μg dose)
Study: 36791792
Drug: Age-related dose
Normalized name: casein, Lactococcus lactis cultured, aged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age-related dose adjustments
Study: 36791986
Drug: Placebo (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (40 mL of normal saline solution)
Study: 36792639
Drug: 0.5% isobaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% isobaric bupivacaine (3 ml)
Study: 36792639
Drug: 0.5% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% levobupivacaine (3 ml)
Study: 36792639
Drug: 0.5% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% hyperbaric bupivacaine (3 ml)
Study: 36792805
Drug: Lisavanbulin administered
Normalized name: Lisavanbulin
DrugBank: Lisavanbulin (DB15224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisavanbulin administered as a 48-hour intravenous infusion at the recommended Phase 2 dose (RP2D) of 70 mg/m²
Study: 36793000
Drug: ESPB (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESPB (20 ml 0.25% bupivacaine)
Study: 36793000
Drug: ESPB +
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESPB + DEX (19 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 µg/kg)
Study: 36793118
Drug: baricitinib 4
Normalized name: baricitinib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: baricitinib 4 mg per day + hydroxychloroquine (HCQ) 400 mg per day
Study: 36793118
Drug: hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hydroxychloroquine (HCQ) 400 mg per day alone
Study: 36794354
Drug: Idecabtagene vicleucel
Normalized name: idecabtagene vicleucel
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idecabtagene vicleucel (ide-cel) at doses of 150, 300, or 450 × 10^6 CAR T cells
Study: 36794691
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) S-ICD implantation
Study: 36794963
Drug: Emerade® 500 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emerade® 500 μg
Study: 36794963
Drug: Emerade® 300 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emerade® 300 μg
Study: 36794963
Drug: Epipen® 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epipen® 0.3 mg
Study: 36795232
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) treatment at week 3
Study: 36795232
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) treatment at week 12
Study: 36795303
Drug: Structured clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured clinical pharmacist-delivered intervention (medication reconciliation and counselling at discharge, and two follow-up sessions at 4 and 8 weeks post-discharge)
Study: 36795843
Drug: Darolutamide plus
Normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darolutamide plus androgen-deprivation therapy and docetaxel
Study: 36795843
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus androgen-deprivation therapy and docetaxel
Study: 36796016
Drug: Oral azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral azacitidine (CC-486) at 300 mg daily for 7 days before C1 of CHOP, and for 14 days before CHOP C2-6 plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Study: 36796016
Drug: Oral azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral azacitidine (CC-486) plus CHOP
Study: 36796498
Drug: Preoperative SABR
Normalized name: Sabril
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative SABR (Stereotactic Ablative Body Radiotherapy) for early-stage breast cancer, details on dosage and duration not available.
Study: 36796641
Drug: Booster antenatal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster antenatal corticosteroids (12 mg betamethasone every 24 hours for 2 days)
Study: 36797036
Drug: Pericapsular nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pericapsular nerve group block (n=30) using 20 mL of adrenalized bupivacaine 0.50%
Study: 36797036
Drug: Periarticular local
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular local anesthetic infiltration (n=30) using 60 mL of adrenalized bupivacaine 0.25%
Study: 36797201
Drug: 15.5 g
Normalized name: ZINC OXIDE 15.5 g in 100 mL TOPICAL LOTION [Vacation SPF 30 Mineral]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15.5 g carbohydrates
Study: 36797201
Drug: 31 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 31 g carbohydrates
Study: 36797356
Drug: BGB-A333 alone
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGB-A333 alone and in combination with tislelizumab
Study: 36797394
Drug: Protective lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective lung ventilation (tidal volume set at 6 ml/Kg predicted body weight, PEEP 6 cmH2O)
Study: 36797481
Drug: Tropifexor 10-90
Normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropifexor 10-90 μg
Study: 36797481
Drug: Tropifexor 140
Normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropifexor 140 μg
Study: 36797481
Drug: Tropifexor 200
Normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropifexor 200 μg
Study: 36797744
Drug: Rivoceranib (apatinib)
Normalized name: Rivoceranib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivoceranib (apatinib) 300 mg once daily in combination with pembrolizumab 200 mg every 3 weeks
Study: 36797990
Drug: ETI therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETI therapy (elexacaftor/tezacaftor/ivacaftor)
Study: 36798001
Drug: Levothyroxine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine treatment for transient congenital hypothyroidism (TCH)
Study: 36798001
Drug: Levothyroxine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine treatment for permanent congenital hypothyroidism (PCH)
Study: 36798001
Drug: Levothyroxine dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine dose of ≤3.95, ≤2.56, ≤2.19 and ≤2.12 μg/kg/day at 6 months, 1, 2 and 3 years of follow-up respectively
Study: 36798676
Drug: Four-session tobacco
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-session tobacco cessation intervention with nicotine replacement therapy (NRT)
Study: 36798676
Drug: Re-engagement with
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-engagement with Quitline treatment
Study: 36798983
Drug: Sham-therapy with
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-therapy with ≥ 5 hours of sleep
Study: 36799346
Drug: Bowel preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel preparation with mannitol
Study: 36799958
Drug: Sertraline, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline, dosage and duration not specified
Study: 36799961
Drug: Ketamine treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine treatment, dosage and duration not specified
Study: 36800277
Drug: CortisolDST 83-137
Approvals — FDA: no, EMA: no, PMDA: no
Description: CortisolDST 83-137 nmol/L
Study: 36800277
Drug: CortisolDST ≥138
Approvals — FDA: no, EMA: no, PMDA: no
Description: CortisolDST ≥138 nmol/L
Study: 36800277
Drug: CortisolDST 50-82
Approvals — FDA: no, EMA: no, PMDA: no
Description: CortisolDST 50-82 nmol/L in patients younger than 65 years
Study: 36800443
Drug: SGN-CD228A (antibody-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGN-CD228A (antibody-drug conjugate with MMAE)
Study: 36800982
Drug: BEAM program
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEAM program (online group therapy and app-based mental health and parenting program)
Study: 36801448
Drug: MSDC-0602K (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSDC-0602K (250 mg)
Study: 36801448
Drug: MSDC-0602K treatment
Normalized name: MSDC-0160
DrugBank: Mitoglitazone (DB11721)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSDC-0602K treatment in ZDF rats
Study: 36802022
Drug: Palovarotene 5
Normalized name: palovarotene 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palovarotene 5 mg